Biogen (BIIB) and Eisai (ESALF) are doing their best to get FDA approval for their Alzheimer's drug aducanumab. However, a closer look at the numbers demonstrates the limited effectiveness of the drug. These numbers further suggest that the current flurry of excitement over aducanumab should be tempered and that investors would be wise to reduce their holdings in the stock.
A little longer exposure to the highest dose of aducanumab for those with the APOE4 gene apparently slowed down the rate of decline from 2% to 25% versus placebo as measured by ADAS-cog (Alzheimer's Disease